Company intelligence / Profile preview

Biosyntia

Ownership: Private
Employees: ~50
Development stage: Commercial

Overview

Biosyntia has developed proprietary fermentation technologies to produce high-purity vitamins and nutraceuticals—most notably BIO-B7™ biotin—offering sustainable alternatives to chemical synthesis. Their products are used in dietary supplements, personal care, food & beverages, and animal nutrition. The company’s approach reduces environmental impact compared to traditional methods by using sugar beet carbohydrates instead of crude oil derivatives. They have filed several patents related to metabolic engineering.

Therapeutic areas: Metabolic DisordersDermatologyOther
Modalities: Fermentation-based production of small molecules (e.g., vitamins such as biotin/Vitamin B7)
Industry: Non-Drug Biotech

Drug pipeline

3 assets

BioB7

Commercial

Indications: Hair health, Skin health

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Biosyntia.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Biosyntia.

Explore the full profile